VentiRx Raises $26.6M, Plans For Acquisition Of TLR Platform March 6, 2007 By Trista Morrison No Comments
VentiRx Raises $26.6M, Plans For Acquisition Of TLR Platform March 6, 2007 By Trista Morrison No Comments
Point Shares Fall On Mixed Phase III, Bad Phase II Update March 2, 2007 By Trista Morrison No Comments
Point Shares Fall On Mixed Phase III, Bad Phase II Update March 2, 2007 By Trista Morrison No Comments
Orthopedic showcase: From gene therapy to treatments for new kinds of battlefield injuries March 1, 2007 By Trista Morrison No Comments
Biotech Drugs Have Allergy Potential, If Risk/Benefit Righ Feb. 28, 2007 By Trista Morrison No Comments
Biotech Drugs Have Allergy Potential, If Risk/Benefit Righ Feb. 28, 2007 By Trista Morrison No Comments
BiPar Raises $35M Series B For PARP Inhibitor Program Feb. 27, 2007 By Trista Morrison No Comments With a $35 million Series B financing in hand, BiPar Sciences Inc. expects to generate Phase II data with lead product candidate BSI-201, advance a second compound into the clinic and get a third product through IND filing. (BioWorld Today)Read More
